Affinity Optimization Assay

Therapeutic monoclonal antibodies (mAbs) are an expanding drug market, especially in the search for new drugs for cancer and chronic diseases. In the drug production process, obtaining the best affinity of mAbs is an important factor in achieving effective and safe therapeutic agents. Our experts in Creative Biolabs are dedicated to providing customized affinity optimization services to help our clients improve the manufacturability of drug candidates.

Introduction of Affinity

As a growing part of the therapeutic field, affinity optimization of mAbs is essential for the development of candidate drugs with the highest clinical success potential. Antibody affinity refers to the intensity of binding of epitopes to a single side-effect region (antigen-binding site) on the antibody. The affinity of mAbs can be accurately measured because they are uniform and selective for a single epitope. High-affinity antibodies bind to antigens quickly, allowing higher sensitivity in analysis and easier to maintain under difficult conditions. In contrast, the binding of low-affinity antibodies to antigens is weak, and antigens are usually not detected in vivo or in the laboratory. However, compared with low-affinity antibodies, high-affinity antibodies are affected by factors such as pH, temperature and buffer composition. Therefore, there are many challenges in optimizing the affinity of mAbs.

Affinity Optimization Assay for mAbs in Creative Biolabs

The production of mAbs with the best affinity for target antigens is an important factor in achieving effective and safe therapeutic agents. A kinetic exclusion assay (KinExA) method for determining the solution affinity of protein/protein interactions has been used to determine the apparent affinity of mAbs to their own targets and the endogenous concentration of the target in serum. Currently, we propose a number of novel methods to optimize the affinity of antibodies. we have developed a random library mutation platform based on in vitro phage display and high-throughput DNA sequencing assays to increase the affinity of different types of antibodies. For instance, we have successfully applied a yeast-displayed random mutagenesis library to optimize the affinity of an anti-IL-17A antibody. Four key amino acids have been changed in the experiment, and the affinity of IL-17A has been increased by about 15 times.

Fig.1 Affinity optimization diagram of anti-IL-17A antibody. (Sun, et al., 2019)

Advantages of Our Technology Platform

Explore a larger antibody sequence space to obtain high-affinity antibodies
Discover better antibody sequences
Effectively and directly screen highly active antibodies
Screen high-affinity antibodies with correct heavy and light chain pairing

Whether you know the best binding strength needed to improve your analysis or you need extensive testing, we can select antibodies according to the binding strength of antibodies to help you optimize your analysis, save time, and ultimately improve your analysis results. If you need any affinity optimization services, please contact us or send us an inquiry.

Reference

Sun, W.; et al. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting. Acta Pharmaceutica Sinica B. 2019.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: